Who
Vimal Kavuru
Director
Company insider
Files Form 4 as: Director and 10% owner, Grace Therapeutics.
In numbers
- Trades disclosed
- 11
- Buys
- 1
- Sells
- 0
- Bought
- $1.3M
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 12 Nov 2021
- Last trade
- 17 Sep 2026
- Last filed
- 21 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Sep 2026filed 21 Sep 2026 | GRCE Grace Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,200 at $0.00 | filing |
| 17 Sep 2026filed 21 Sep 2026 | GRCE Grace Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,200 at $0.00 | filing |
| 8 Jan 2026filed 12 Jan 2026 | GRCE Grace Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 8 Jan 2026filed 12 Jan 2026 | GRCE Grace Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 9 May 2025filed 13 May 2025 | GRCE Grace Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 19 Dec 2023filed 20 Dec 2023 | GRCE Grace Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 25 Sep 2023filed 27 Sep 2023 | GRCE Grace Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | $55K422,732 at $0.13 | filing |
| 25 Sep 2023filed 27 Sep 2023 | GRCE Grace TherapeuticsBiotechnology | SEC FORM 4 Bought | $1.3M676,371 at $1.85 | filing |
| 14 Jul 2023filed 18 Jul 2023 | GRCE Grace Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
| 28 Sep 2022filed 30 Sep 2022 | GRCE Grace Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 12 Nov 2021filed 16 Nov 2021 | GRCE Grace Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —42,100 at $0.00 | filing |
News
Grace Therapeutics (NASDAQ:GRCE) Upgraded at Wall Street ZenGRCE · themarketsdaily.com · 15 Oct 2026
0 headlines in the last 90 days name Vimal Kavuru; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.